Implementing the national invasive cervical cancer audit: a local perspective.
OBJECTIVE
To monitor the effectiveness of the cervical screening programme and identify suboptimal management in order to improve patient care.


METHODS
Retrospective study.


METHODS
A university hospital serving a population of 1 million people.


METHODS
All women diagnosed with a cervical cancer between 2003 and 2006.


METHODS
Analysis of data from invasive cervical cancer reviews.


METHODS
Categorisation of cervical cancer cases according to the Invasive Cervical Cancer Audit classification.


RESULTS
Eighty-seven women were diagnosed with cervical cancer during the 3-year study period. The 'lapsed attender' group accounted for the greatest number of cases (30%), followed by screen detected (26%), interval cancers (13%), never attended (12%), lost to follow-up (10%) and never invited (9%). Women who had never attended for cytology presented with higher stage disease, stage-II or above, compared with the screen-detected cases: 60% were stage II or above, compared with 13.0%, Chi-square P = 0.018. The most frequently identified screening programme problem was patient compliance, which was determined to be the principle contributing factor in 39 cases (45%) and a secondary factor in a further ten cases.


CONCLUSIONS
The categorisation of cervical cancer cases has the potential of yielding invaluable information for improving programme effectiveness. Patient compliance is the greatest challenge to the screening programme, and the need for regular screening and adherence to follow-up regimens needs to be reinforced in order to maximise the efficacy of the national screening programme.
Moss
E L
EL
University Hospital of North Staffordshire, Stoke on Trent, UK.
Pearmain
P
P
Askew
S
S
Owen
G
G
Reynolds
T M
TM
Prabakar
I M
IM
Douce
G
G
Parkes
J
J
Menon
V
V
Todd
R W
RW
Redman
C W E
CW
D000230:Adenocarcinoma / Q000473:pathology / Q000517:prevention & control*; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000458:organization & administration*; D008485:Medical Audit; D008875:Middle Aged; D010349:Patient Compliance; D012189:Retrospective Studies; D006113:United Kingdom; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000517:prevention & control*; D014626:Vaginal Smears; D055815:Young Adult